Early clinical results with the neuroleptic roxindole (EMD 49,980) in the treatment of schizophrenia--an open study.
The neuroleptic effect and tolerability of roxindole (EMD 49,980), an agonist of the dopamine-D2 autoreceptor, was studied during a 4 week treatment period in 7 patients with paranoid-hallucinatory schizophrenia (ICD-9: 295.3). In patients with a daily dosage of up to 4.5 mg/day, there was no improvement as measured with the total score of the BPRS scale. In contrast, patients with a daily dosage of up to 30 mg/day showed a slight improvement, especially in items associated with negative symptoms. In 3 patients there were slight adverse events (dizziness, hypersalivation, hypotonia, nausea/vomiting, miction disturbance) which were probably connected with the intake of roxindole.
Department of Psychiatry, University Bonn, Germany.
S
S
Kasper
J
J
Fuger
H J
HJ
Zinner
J
J
Bäuml
H J
HJ
Möller
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004361:Drug Tolerance; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D000078183:Oxindoles; D011569:Psychiatric Status Rating Scales; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D007211:Indoles; D000078183:Oxindoles; D011725:Pyridines; C059613:roxindole